Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxybutynin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : Oxybutynin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elobixibat,Inapplicable
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2023
Lead Product(s) : Elobixibat,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Budesonide,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
Details : Decoy20 is single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
July 26, 2021
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Salbutamol Sulphate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 31, 2020
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 01, 2016
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable